3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Blisibimod, Placebo - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Withdrawn | Anthera Pharmaceuticals | 2014-12-01 | 2015-07-30 | |
| Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens Retinoic acid, Standard of care - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2012-01-01 | 2017-02-23 | |
| Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab Standard of care treatment, eculizumab - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2011-05-01 | 2017-02-23 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Granulomatosis with Polyangiitis (1) · Microscopic Polyangiitis (1) · Vasculitis (1)
Autoimmune Diseases (3) · Cardiovascular Diseases (3) · Immune System Diseases (3) · Skin Diseases (3) · Skin Diseases, Vascular (3) · Skin and Connective Tissue Diseases (3) · Vascular Diseases (3) · Vasculitis (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cerebral Small Vessel Diseases (1) · Cerebrovascular Disorders (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1)
AMG623 peptibody (1) · Adenosine Triphosphate (1) · Azathioprine (1) · Cyclophosphamide (1) · Mycophenolic Acid (1) · Standard of Care (1) · Tretinoin (1) · eculizumab (1)
University of North Carolina, Chapel Hill (2) · Anthera Pharmaceuticals (1)
United States (2)
P01DK058335 (2)